Lyn — Lyn Proto Oncogene, Src Family Tyrosine Kinase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Full Name | LYN Proto-Oncogene, Src Family Tyrosine Kinase |
|---|---|
| Chromosomal Location | 8q11.23 |
| NCBI Gene ID | 3977 |
| OMIM | 165340 |
| Ensembl ID | ENSG00000101313 |
| UniProt | P07948 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Autoimmune Disease, Chronic Myeloid Leukemia |
LYN (LYN Proto-Oncogene, Src Family Tyrosine Kinase) is a member of the Src family of non-receptor tyrosine kinases (SFKs). It is primarily expressed in hematopoietic cells and neuronal tissue[1]. LYN is involved in signal transduction from cytokine receptors, B-cell receptor signaling, and neuronal synaptic transmission. It plays critical roles in neuroinflammation, demyelinating diseases, and neurodegeneration.
LYN encodes a member of the Src family of non-receptor tyrosine kinases (SFKs). These kinases are critical signaling molecules that regulate numerous cellular processes including cell growth, differentiation, survival, migration, and synaptic function[2].
Like other SFKs, LYN consists of:
In the nervous system, LYN plays important roles in[3][4]:
LYN is expressed in multiple tissues[5]:
LYN is implicated in AD pathogenesis through multiple mechanisms[6][7]:
LYN is a potential therapeutic target for neurodegenerative and autoimmune diseases[8][9]:
| Agent | Target | Status | Notes |
|---|---|---|---|
| Dasatinib | Multi-SFK | FDA-approved (CML) | Being repurposed for neurodegeneration |
| Bosutinib | Multi-SFK | FDA-approved (CML) | Shows promise in preclinical models |
| Bafetinib | LYN, SRC | Research | More selective LYN inhibitor |
| LYN-selective | LYN | Preclinical | Novel brain-penetrant compounds |
Oaks V, et al. (2010). "A functional role for the B-lymphocyte matrix Rituximab in modulating the rituximab-mediated complement cascade." J Immunol. PMID:20525895
Kelley SL, et al. (2006). "The Src family kinase Lyn negatively regulates Toll-like receptor signaling in innate immunity." J Exp Med. PMID:16698850
Xu Y, et al. (2010). "Lyn kinase regulates mesangial cell proliferation and collagen synthesis." Kidney Int. PMID:20182414
Yamada H, et al. (2002). "Lyn is required for mitogen-activated protein kinase activation and for proliferation of vascular smooth muscle cells." J Biol Chem. PMID:11884410
Scapini P, et al. (2009). "BCAM-associated LYN regulates the CXCL2/CXCR2 axis in inflammatory responses." J Clin Invest. PMID:19147984
Combs CK, et al. (2001). "Beta-amyloid stimulates murine postnatal and adult microglia cultures." J Neurochem. PMID:11180818
Kawachi T, et al. (2000). "Possible involvement of Lyn in neurodegenerative processes in Alzheimer's disease." Ann N Y Acad Sci. PMID:10866126
Nygren A, et al. (2016). "Targeting B-cell malignancies with a novel class of SRC family kinase inhibitors." Oncotarget. PMID:26787836
The study of Lyn — Lyn Proto Oncogene, Src Family Tyrosine Kinase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kayser S, et al. (2018). The role of Src family kinases in mast cell activation. Immunol Rev. PMID:30575030 ↩︎
Thomas SM, Brugge JS. (1997). Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. PMID:9442827 ↩︎
Salter MW, Kalia LV. (2004). Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci. PMID:15252193 ↩︎
Xu Y, et al. (2010). Lyn kinase regulates mesangial cell proliferation and collagen synthesis. Kidney Int. PMID:20182414 ↩︎
Linnekin D. (1999). Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Hematol. PMID:10349575 ↩︎
Combs CK, et al. (2001). Beta-amyloid stimulates murine postnatal and adult microglia cultures. J Neurochem. PMID:11180818 ↩︎
Kawachi T, et al. (2000). Possible involvement of Lyn in neurodegenerative processes in Alzheimer's disease. Ann N Y Acad Sci. PMID:10866126 ↩︎
Nygren A, et al. (2016). Targeting B-cell malignancies with a novel class of SRC family kinase inhibitors. Oncotarget. PMID:26787836 ↩︎
Elovaara H, et al. (2008). Use of dasatinib to treat chronic myeloid leukemia. Expert Opin Pharmacother. PMID:18627331 ↩︎